CONRAD engages in a Monitoring and Evaluation plan meant to measure CONRAD’s progress in the proposed research and development activities.  Successive and parallel stages of evaluation are undertaken, including CONRAD technical monitors’ assessments, periodic meetings of the Preclinical Working Group, Product Development Group, Clinical Team, Directors, and whole staff. Outside oversight will be provided by CONRAD’s Scientific Advisory Committee (SAC), a group of prominent investigators with expertise in HIV virology, STDs, preclinical testing and clinical research, pharmaceutical sciences, reproductive biology, obstetrics-gynecology, and microbicides.

Priority areas for CONRAD funding are:

• Chemical barriers for women that prevent pregnancy and/or STIs
• Systemic methods for women and men
• Mechanical barriers for women

Projects in other areas may also considered for support, particularly those that would likely lead to increase contraceptive use in developing countries, such as developing generic products for distribution by public sector family planning programs at lower cost than trade-name products.

The CONRAD staff reviews progress on individual projects using financial and semiannual technical progress reports. The program as a whole is reviewed annually by CONRAD's Technical Advisory Committee, which consists of experts in the reproductive sciences, family planning, and women's issues.

Guidelines for Submitting Aplications

See also

Important differences  between CONRAD funding services

(Includes Facilities, administrative and cost allowances)

For inquiries regarding funding opportunities at CONRAD, please contact Doug Colvard at 703.524.4744 or dcolvard@conrad.org